Welcome back to Plenary Session Podcast.

I believe this is actually Season 5, Episode 45.

Wow.

It's been a long time, hasn't it?

I think I started this in 2018 in the fall.

And it's been going all these years.

Steadfast, gaining popularity.

And we thank you here at Plenary Session podcast because we are the most

popular podcast among oncologists, which is a very tiny market, a very tiny market. But in that

market, we're number one within that market. It's a bit like when people say multiple myeloma is

the most common cancer of plasma cells.

It's the most common plasma cell cancer.

I mean, there are lots of cancers that are much more common, but if it's a cancer of a plasma cell,

there's nothing more common than this.

And so that's sort of what it's like.

Well, welcome.

Today, I've got a lot in store for you.

This is going to be a long episode because I'm going to put together things that I've done.

So one hot off the press just recorded, just this minute, Karma 3, Karma 3.

Ida Cells versus Standard Therapy, whatever the hell that is, investigators choice, choice. The good stuff, well, minus the actual good

stuff, which is a New England Journal of Medicine publication. That is the talk of the town,

and this is about CAR-T. But unlike the original car tea, this one doesn't cure anybody. It doesn't

...